HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verhoeff, N. P.L.G. Articles by Houle, S. Search for Related Content PubMed PubMed Citation Articles by Verhoeff, N. P.L.G. Articles by Houle, S.

In-Vivo Imaging of Alzheimer Disease ß-Amyloid With [¹¹C]SB-13 PET

Received August 12, 2004; revised August 28, September 1, 2004; accepted September 2, 2004. From the Vivian Rakoff PET Centre, Centre for Addiction and Mental Health (CAMH) (NPLGV,AAW,DH,KS,SH); the Kunin-Lunenfeld Applied Research Centre, Baycrest Centre for Geriatric Care (NPLGV,ST,LT); the Department of Psychiatry, University of Toronto, Ontario, Canada (NPLGV,AAW,ST); and the Department of Radiology, University of Pennsylvania, Philadelphia, PA (HFK,MPK). Send correspondence to Nicolaas Paul L.G. Verhoeff, M.D., Ph.D., FRCPC, Assistant Professor, Department of Psychiatry, University of Toronto, Clinician-Scientist, Kunin-Lunenfeld Applied Research Unit, Posluns Building, Room 762, Baycrest Centre for Geriatric Care, 3560 Bathurst St., Toronto, Ontario M6A 2E1, Canada. e-mail: pverhoeff{at}klaru-baycrest.on.ca
© 2004 American Association for Geriatric Psychiatry

Objective: In-vivo imaging of ß-amyloid plaques (Aß) may improve both early detection of Alzheimer disease (AD) and efficacy assessment of new treatments for AD. The authors' aim was to develop a novel Aß-specific positron-emission tomography (PET) tracer. Methods: Five female AD patients (54–77 years old) and six healthy female comparison subjects (53–74 years old), completed 2-hour PET scans after intravenous injection of 10 mCi of both the stilbene [¹¹C]SB-13 and the benzothiazole [¹¹C]6-OH-BTA-1 (also known as [¹¹C]PIB). Kinetic analyses were performed on the resulting time-activity curves to derive Aß binding-potential estimates, using as input function either the unmetabolized tracer concentration in venous plasma from a two-tissue compartment model or the density of radioactivity in the cerebellum. Authors compared the binding characteristics of the two radiotracers. Results: The two radiotracers demonstrated similar binding properties with respect to regional distribution of retention (increased retention in the frontal and posterior temporal-inferior parietal association cortices in the AD patients, but not in the comparison subjects). Our preliminary PET data indicate that [¹¹C]SB-13 may be similar to [¹¹C]PIB in discriminating AD patients from comparison subjects. Conclusions: [¹¹C]SB-13 is an effective PET tracer for fibrillar Aß imaging in vivo, with similar performance as [¹¹C]PIB. Future research directions include evaluation of tracer in larger AD patient samples and in subjects with amnestic mild cognitive impairment, evaluation of arterial input function, and comparison with other tracers, such as [¹⁸F]FDG as they relate to cognitive functioning.

Key Words: Neuroimaging • PET • Radiotracers • Diagnostic Techniques

This article has been cited by other articles:

				P Edison, C C Rowe, J O Rinne, S Ng, I Ahmed, N Kemppainen, V L Villemagne, G O'Keefe, K Nagren, K R Chaudhury, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J. Neurol. Neurosurg. Psychiatry, December 1, 2008; 79(12): 1331 - 1338. [Abstract] [Full Text] [PDF]

				M. D. Ikonomovic, W. E. Klunk, E. E. Abrahamson, C. A. Mathis, J. C. Price, N. D. Tsopelas, B. J. Lopresti, S. Ziolko, W. Bi, W. R. Paljug, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain, June 1, 2008; 131(6): 1630 - 1645. [Abstract] [Full Text] [PDF]

				C. R. Jack Jr, V. J. Lowe, M. L. Senjem, S. D. Weigand, B. J. Kemp, M. M. Shiung, D. S. Knopman, B. F. Boeve, W. E. Klunk, C. A. Mathis, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain, March 1, 2008; 131(3): 665 - 680. [Abstract] [Full Text] [PDF]

				J. L. Cummings, R. Doody, and C. Clark Disease-modifying therapies for Alzheimer disease: Challenges to early intervention Neurology, October 16, 2007; 69(16): 1622 - 1634. [Abstract] [Full Text] [PDF]

				J. Maeda, B. Ji, T. Irie, T. Tomiyama, M. Maruyama, T. Okauchi, M. Staufenbiel, N. Iwata, M. Ono, T. C. Saido, et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography J. Neurosci., October 10, 2007; 27(41): 10957 - 10968. [Abstract] [Full Text] [PDF]

				A. Lockhart, J.R. Lamb, T. Osredkar, L.I. Sue, J.N. Joyce, L. Ye, V. Libri, D. Leppert, and T.G. Beach PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis Brain, October 1, 2007; 130(10): 2607 - 2615. [Abstract] [Full Text] [PDF]

				W. E. Klunk, J. C. Price, C. A. Mathis, N. D. Tsopelas, B. J. Lopresti, S. K. Ziolko, W. Bi, J. A. Hoge, A. D. Cohen, M. D. Ikonomovic, et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees J. Neurosci., June 6, 2007; 27(23): 6174 - 6184. [Abstract] [Full Text] [PDF]

				C. C. Rowe, S. Ng, U. Ackermann, S. J. Gong, K. Pike, G. Savage, T. F. Cowie, K. L. Dickinson, P. Maruff, D. Darby, et al. Imaging {beta}-amyloid burden in aging and dementia Neurology, May 15, 2007; 68(20): 1718 - 1725. [Abstract] [Full Text] [PDF]

				S. Ng, V. L. Villemagne, S. Berlangieri, S.-T. Lee, M. Cherk, S. J. Gong, U. Ackermann, T. Saunder, H. Tochon-Danguy, G. Jones, et al. Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease J. Nucl. Med., April 1, 2007; 48(4): 547 - 552. [Abstract] [Full Text] [PDF]

				Y. Kudo, N. Okamura, S. Furumoto, M. Tashiro, K. Furukawa, M. Maruyama, M. Itoh, R. Iwata, K. Yanai, and H. Arai 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients J. Nucl. Med., April 1, 2007; 48(4): 553 - 561. [Abstract] [Full Text] [PDF]

				P. Edison, H. A. Archer, R. Hinz, A. Hammers, N. Pavese, Y. F. Tai, G. Hotton, D. Cutler, N. Fox, A. Kennedy, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study Neurology, February 13, 2007; 68(7): 501 - 508. [Abstract] [Full Text] [PDF]

				C. R. Jack Jr, M. Marjanska, T. M. Wengenack, D. A. Reyes, G. L. Curran, J. Lin, G. M. Preboske, J. F. Poduslo, and M. Garwood Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research Neuroscientist, February 1, 2007; 13(1): 38 - 48. [Abstract] [PDF]

				G. W. Small, V. Kepe, L. M. Ercoli, P. Siddarth, S. Y. Bookheimer, K. J. Miller, H. Lavretsky, A. C. Burggren, G. M. Cole, H. V. Vinters, et al. PET of Brain Amyloid and Tau in Mild Cognitive Impairment N. Engl. J. Med., December 21, 2006; 355(25): 2652 - 2663. [Abstract] [Full Text] [PDF]

				N. M. Kemppainen, S. Aalto, I. A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease Neurology, November 14, 2006; 67(9): 1575 - 1580. [Abstract] [Full Text] [PDF]

				H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, I. Savitcheva, A. Wall, A. Ringheim, B. Langstrom, and A. Nordberg Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain, November 1, 2006; 129(11): 2856 - 2866. [Abstract] [Full Text] [PDF]

				T. Sunderland, H. Hampel, M. Takeda, K. T. Putnam, and R. M. Cohen Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready? J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 172 - 179. [Abstract] [PDF]

				G. W. Small Diagnostic Issues in Dementia: Neuroimaging as a Surrogate Marker of Disease J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 180 - 185. [Abstract] [PDF]

				M. A. Mintun, G. N. LaRossa, Y. I. Sheline, C. S. Dence, S. Y. Lee, R. H. Mach, W. E. Klunk, C. A. Mathis, S. T. DeKosky, and J. C. Morris [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease Neurology, August 8, 2006; 67(3): 446 - 452. [Abstract] [Full Text] [PDF]

				B. J. Lopresti, W. E. Klunk, C. A. Mathis, J. A. Hoge, S. K. Ziolko, X. Lu, C. C. Meltzer, K. Schimmel, N. D. Tsopelas, S. T. DeKosky, et al. Simplified Quantification of Pittsburgh Compound B Amyloid Imaging PET Studies: A Comparative Analysis J. Nucl. Med., December 1, 2005; 46(12): 1959 - 1972. [Abstract] [Full Text] [PDF]